Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Electromed (ELMD) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Electromed (ELMD) over the last 17 years, with Q4 2025 value amounting to $13.8 million.

  • Electromed's Cash & Equivalents fell 1505.39% to $13.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $13.8 million, marking a year-over-year decrease of 1505.39%. This contributed to the annual value of $15.3 million for FY2025, which is 493.16% down from last year.
  • As of Q4 2025, Electromed's Cash & Equivalents stood at $13.8 million, which was down 1505.39% from $14.1 million recorded in Q3 2025.
  • Electromed's 5-year Cash & Equivalents high stood at $16.2 million for Q4 2024, and its period low was $6.0 million during Q3 2022.
  • Over the past 5 years, Electromed's median Cash & Equivalents value was $11.3 million (recorded in 2021), while the average stood at $11.2 million.
  • Per our database at Business Quant, Electromed's Cash & Equivalents tumbled by 4537.34% in 2022 and then skyrocketed by 11812.26% in 2024.
  • Quarter analysis of 5 years shows Electromed's Cash & Equivalents stood at $10.5 million in 2021, then tumbled by 34.01% to $6.9 million in 2022, then soared by 51.02% to $10.4 million in 2023, then surged by 55.6% to $16.2 million in 2024, then decreased by 15.05% to $13.8 million in 2025.
  • Its Cash & Equivalents stands at $13.8 million for Q4 2025, versus $14.1 million for Q3 2025 and $15.3 million for Q2 2025.